333 related articles for article (PubMed ID: 17191751)
21. Safety of sublingual immunotherapy with a monomeric allergoid in very young children.
Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G
Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951
[No Abstract] [Full Text] [Related]
22. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
23. Sublingual immunotherapy in polysensitized patients: effect on quality of life.
Ciprandi G; Cadario G; Valle C; Ridolo E; Verini M; Di Gioacchino M; Minelli M; Gangemi S; Sillano V; Colangelo C; Pravettoni V; Pellegrino R; Borrelli P; Fiorina A; Carosso A; Gasparini A; Riario-Sforza GG; Incorvaia C; Puccinelli P; Scurati S; Frati F
J Investig Allergol Clin Immunol; 2010; 20(4):274-9. PubMed ID: 20815304
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study.
Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C
Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
26. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children.
Tripodi S; Di Rienzo Businco A; Benincori N; Scala G; Pingitore G
Int Arch Allergy Immunol; 2006; 139(2):149-52. PubMed ID: 16374025
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
Stelmach I; Kaczmarek-Woźniak J; Majak P; Olszowiec-Chlebna M; Jerzynska J
Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016
[TBL] [Abstract][Full Text] [Related]
30. Dose-dependent clinical and immunological efficacy of sublingual immunotherapy with mite monomeric allergoid.
Di Gioacchino M; Cavallucci E; Ballone E; Cervone M; Di Rocco P; Piunti E; Filardo GS; Turi MC; Mangifesta R; Quecchia C; Mistrello G; Braga M; Petrarca C
Int J Immunopathol Pharmacol; 2012; 25(3):671-9. PubMed ID: 23058017
[TBL] [Abstract][Full Text] [Related]
31. Sublingual specific immunotherapy reduces PBMC proliferations.
Fenoglio D; Puppo F; Cirillo I; Vizzaccaro A; Ferrera A; Tosca MA; Marseglia G; Ciprandi G
Eur Ann Allergy Clin Immunol; 2005 Apr; 37(4):147-51. PubMed ID: 15916016
[TBL] [Abstract][Full Text] [Related]
32. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.
Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L
Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
Rossi RE; Monasterolo G
Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children.
Caramia G; Franceschini F; Cimarelli ZA; Ciucchi MS; Gagliardini R; Ruffini E
Allerg Immunol (Paris); 1996 Nov; 28(9):308-10. PubMed ID: 8986246
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of grass pollen tablets in sublingual immunotherapy--a phase-1 study.
Larsen TH; Poulsen LK; Melac M; Combebias A; Andre C; Malling HJ
Allergy; 2006 Oct; 61(10):1173-6. PubMed ID: 16942564
[TBL] [Abstract][Full Text] [Related]
37. Short-term efficacy of nasal immunotherapy.
Palma-Carlos AG; Santos AS; Pregal A
Allerg Immunol (Paris); 1998 Jan; 30(1):14-7. PubMed ID: 9503098
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice.
Ferrés J; Justicia JL; García MP; Muñoz-Tudurí M; Alvà V
Allergol Immunopathol (Madr); 2011; 39(3):122-7. PubMed ID: 20570032
[TBL] [Abstract][Full Text] [Related]
39. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children.
Dehlink E; Eiwegger T; Gerstmayr M; Kampl E; Bohle B; Chen KW; Vrtala S; Urbanek R; Szépfalusi Z
Clin Exp Allergy; 2006 Jan; 36(1):32-9. PubMed ID: 16393263
[TBL] [Abstract][Full Text] [Related]
40. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
